Table 1.
Patient characteristics
| IL-2 RB-treated n=17 |
ATG-treated n=14 |
p value | |
|---|---|---|---|
| Recipient age (years old) | 52±10 | 45±13 | 0.09 |
| Female gender | 6/17 (35.3) | 8/14 (57.1) | 0.22 |
| Caucasian race | 11/17 (64.7) | 11/14 (78.6) | 0.40 |
| Prior pregnancies | 2/6 (33.3) | 4/8 (50.0) | 0.63 |
| Re-transplantation | 2/17 (11.8) | 3/14 (21.4) | 0.47 |
| Dialysis duration (months) | 42±26 | 39±30 | 0.75 |
| Pre-transplant PRA class 1 or 2 >10% | 3/17 (17.7) | 5/14 (35.7) | 0.41 |
| Deceased donor | 14/17 (82.4) | 12/14 (85.7) | 0.80 |
| HLA mismatches | 4.0±1.9 | 3.6±1.7 | 0.52 |
| Pre-transplant (weakly) positive XM | 2/17 (11.8) | 2/14 (14.3) | 1.00 |
| Follow up time (months) | 22±5 | 19±8 | 0.23 |
| Estimated GFR at last follow up (ml/min/1.73 m2) | 54±20 | 56±25 | 0.82 |
| Average tacrolimus levels* (ng/ml) | 10.4±2.3 | 9.0±1.7 | 0.18 |
| ACR or AHR | 1/17 (5.9) | 0/14 (0) | 1.00 |
| BK/CMV viremia | 3/17 (17.7) | 4/14 (28.6) | 0.67 |
- Data presented as n (%) for categorical variables or mean±SD for continuous variables;
- PRA is panel of reactive antibodies, CNI is calcineurin inhibitors, GFR is glomerular filtration rate
*
Average of trough levels at same time points used for study (1, 3 and 6 months post transplant)